Gastroenterology
Volume 137, Issue 6 , Pages 1869-1876 , December 2009

Cost-Effectiveness of Endoscopic Screening Followed by Surveillance for Barrett's Esophagus: A Review

  • Josephine M. Barbiere
    • ,
  • Georgios Lyratzopoulos

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Dr George Lyratzopoulos, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, University Forvie Site Robinson Way, Cambridge, CB2 2SR, United Kingdom

References 

  1. Thomas T, Abrams KR, De Caestecker JS, et al. Meta analysis: cancer risk in Barrett's Oesophagus. Aliment Pharmacol Ther. 2007;26:1465–1477
  2. Lepage C, Rachet B, Jooste V, et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103:2694–2699
  3. Newnham A, Quinn MJ, Babb P, et al. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971–1998. Aliment Pharmacol Ther. 2003;17:665–676
  4. Sihvo EI, Salminen JT, Rämö OJ, et al. The epidemiology of oesophageal adenocarcinoma: has the cancer of gastric cardia an influence on the rising incidence of oesophageal adenocarcinoma?. Scand J Gastroenterol. 2000;35:1082–1086
  5. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053
  6. Brewster DH, Fraser LA, McKinney PA, Black RJ. Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland. Br J Cancer. 2000;83:387–390
  7. Newnham A, Quinn MJ, Babb P, et al. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther. 2003;17:655–664
  8. Eloubeidi MA, Mason AC, Desmond RA, et al. Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. Am J Gastroenterol. 2003;98:1627–1633
  9. Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett's Oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585–1594
  10. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's Oesophagus in Olmsted County, Minnesota. Gut. 2001;48:304–309
  11. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831
  12. Sampliner RE. A population prevalence of Barrett's esophagus—finally. Gastroenterology. 2005;129:2101–2103
  13. Somerville M, Garside R, Pitt M, et al. Surveillance of Barrett's oesophagus: is it worthwhile?. Eur J Cancer. 2008;44:588–599
  14. British Society Of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus (A Report of the Working Party of the British Society of Gastroenterology). http://www.bsg.org.uk/pdf_word_docs/Barretts_Oes.pdfAugust 2005;Accessed April 2009
  15. Wang KK, Sampliner RE The Practice Parameters Committee of the American College of Gastroenterology. Practice Guidelines (Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus). Am J Gastroenterol. 2008;103:788–797
  16. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's Oesophagus: observational study. BMJ. 2000;321:1252–1255
  17. Cook MB, Wild CP, Everett SM, et al. Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2007;16:2090–2096
  18. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?. Am J Gastroenterol. 2000;95:2086–2093
  19. Sharma P, Sidorenko EI. Are screening and surveillance for Barrett's oesophagus really worthwhile?. Gut. 2005;54(suppl 1):i27–i32
  20. Spechler SJ, Barr H. Review article: screening and surveillance of Barrett's oesophagus: what is a cost-effective framework?. Aliment Pharmacol Ther. 2004;19(suppl 1):49–53
  21. Inadomi JM, Rubenstein JH. The cost-effectiveness of screening and surveillance to decrease mortality from esophageal adenocarcinoma. In:  Sharma P,  Sampliner R editor. Barrett's esophagus and esophageal adenocarcinoma. 2nd ed.. Hoboken, NJ: Wiley-Blackwell; 2009;p. 124–138
  22. Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2005;22:135–146
  23. Rubenstein JH, Inadomi JM. Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. J Clin Gastroenterol. 2006;40:109–115
  24. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176–186
  25. Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2004;2:868–879
  26. Rubenstein JH, Inadomi JM, Brill JV, et al. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol. 2007;5:312–318
  27. Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol. 2007;5:319–325
  28. Nietert PJ, Silverstein MD, Mokhashi MS, et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc. 2003;57:311–318
  29. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus. 2007;20:516–522
  30. Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc. 2008;68:35–40
  31. Caygill CP, Watson A, Reed PI, et al. Characteristics and regional variations of patients with Barrett's oesophagus in the UK. Eur J Gastroenterol Hepatol. 2003;15:1217–1222
  32. Vieth M, Schubert B, Lang-Schwarz K, et al. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy. 2006;38:1201–1205
  33. Gatenby PA, Caygill CP, Ramus JR, et al. Short segment columnar-lined oesophagus: an underestimated cancer risk? (A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk). Eur J Gastroenterol Hepatol. 2007;19:969–975
  34. Leiferman JA, Pheley AM. The effect of mental distress on women's preventive health behaviors. Am J Health Promot. 2006;20:196–199
  35. Brett J, Bankhead C, Henderson B, et al. The psychological impact of mammographic screening (A systematic review). Psychooncology. 2005;14:917–938
  36. Gerson LB, Ullah N, Hastie T, et al. Does cancer risk affect health-related quality of life in patients with Barrett's esophagus?. Gastrointest Endosc. 2007;65:31–35
  37. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett's oesophagus: a reaffirmation. Hum Pathol. 2001;32:368–378
  38. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut. 2002;51:671–676
  39. Eloubeidi MA, Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol. 2000;95:1881–1887
  40. Gerson LB, Ullah N, Hastie T, et al. Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:534–536
  41. Macran S, Wileman S, Barton G, et al. The development of a new measure of quality of life in the management of gastro-oesophageal reflux disease: the Reflux questionnaire. Qual Life Res. 2007;16:331–343
  42. NHS Information Centre & Office for National Statistics. Breast Screening Programme England 2006–07. http://www.ic.nhs.uk/webfiles/publications/breastscreening0607/Breast%20Screening%20Bulletin%202006-07.pdfAccessed April 2009
  43. Shaheen NJ, Inadomi JM, Overholt BF, et al. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? (A cost effectiveness analysis). Gut. 2004;53:1736–1744
  44. Vij R, Triadafilopoulos G, Owens DK, et al. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc. 2004;60:739–756
  45. Murray L, Sedo A, Scott M, et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut. 2006;55:1390–1397
  46. Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res. 2007;13:659–665
  47. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2006;55:1810–1820
  48. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67
  49. Chao DL, Sanchez CA, Galipeau PC, et al. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res. 2008;14:6988–6995
  50. Peters CJ, Fitzgerald RC. Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2007;25:1253–1269
  51. Quera R, O'Sullivan K, Quigley EM. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?. Endoscopy. 2006;38:162–169
  52. Lagergren J, Ye W, Bergström R, et al. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA. 2000;284:961–962
  53. Pharoah PD, Antoniou AC, Easton DF, et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358:2796–2803
  54. Lao-Sirieix P, Rous B, O'Donovan M, et al. Non-endoscopic immunocytological screening test for Barrett's oesophagus. Gut. 2007;56:1033–1034
  55. Sir Liam Donaldson, Chief Medical Officer. On the State of Public Health: Annual Report of the Chief Medical Officer 2007 (Department of Health, 2008). http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/AnnualReports/DH_086176Accessed April 2009
  56. Jankowski J, Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ. 2006;332:1512
  57. Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007;99:545–557

 Conflicts of interest The authors disclose no conflicts.

PII: S0016-5085(09)01833-2

doi: 10.1053/j.gastro.2009.10.011

Gastroenterology
Volume 137, Issue 6 , Pages 1869-1876 , December 2009

Article Tools

* Image Usage & Resolution